EFS and OS. (A) EFS for patients included in the PONALFIL trial from enrollment to failure of achieving CHR at week 6, lack of molecular response before HSCT, molecular or hematologic relapse or death by any cause. (B) OS for patients form diagnosis to death or last follow-up.